biotech – Page 2

Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal

5 months ago talkbio0Tagged Age-Related Diseases, biotech, biotech merger, Clinical Development, FutureTech II, Longevity, Nasdaq, Public Listing, SPAC

Longevity Biotech; Nasdaq; SPAC deal; public listing; FutureTech II Acquisition Corp.; clinical development; biotech merger; age-related diseases

GSK Licenses Experimental Shigella Vaccine to Bharat Biotech for Development and Distribution

6 months ago talkbio0Tagged Bharat, biotech, GMMA platform, low, Microbicides, middle-income countries, Resistance (Psychotherapeutic), Shigella Infections, Shigella Vaccines, SmithKline Beecham, vaccine licensing

GSK; Bharat Biotech; Shigella vaccine; altSonflex1-2-3; vaccine licensing; Shigellosis; GMMA platform; antimicrobial resistance; low and middle-income countries

Novo Nordisk CEO Departs Amid Weight-Loss Drug Market Pressures; Flagship Biotech Appoints CEO from Scholar Rock

6 months ago talkbio0Tagged Appointments, biotech, CEO, Challenge, departure - ActRelationshipType, Eli Lilly competition, Flagship, Lars Fruergaard Jørgensen, Market, Nordisk, Obesity, Scholar Rock

Novo Nordisk; CEO departure; Lars Fruergaard Jørgensen; obesity drugs; weight-loss market; Eli Lilly competition; market challenges; Flagship Biotech; CEO appointment; Scholar Rock

AstraZeneca’s China woes recede as focus shifts to upcoming readouts

7 months ago talkbio0Tagged Acquisition, Beijing, biotech, China, China legal issues resolution, FibroGen, Fine - adjective, global strategic R&D center, Investments, Manufacturing, partnerships, R&D

$2.5 billion R&D investment in Beijing, Global strategic R&D center, China legal issues resolution, Biotech partnerships, Manufacturing expansion, $8 million potential fine, FibroGen China acquisition

Biotech and Pharma Job Cuts: Opthea and Pfizer Restructure Amid Industry Challenges

8 months ago talkbio0Tagged biotech, Clinical Trial Failures, Cost savings programs, Glycogen storage disease type II, Industry, Opthea layoffs, Pfizer, Pfizer staff, Pharma, restructuring

Opthea layoffs 2025 , Pfizer staff reduction , Biotech job cuts , Pharma restructuring , Clinical trial failures , Wet AMD treatment , Cost savings programs , Pfizer San Diego layoffs , Biotech industry challenges

Tempest Seeks Strategic Partners to Launch Phase 3 Liver Cancer Trial Amid Funding Challenges

8 months ago talkbio0Tagged altretamine/cisplatin/cyclophosphamide protocol, amezalpat, Avastin, biotech, Clearance, Clinical Oncology, Liver and Intrahepatic Biliary Tract Carcinoma, partnerships, Peroxisome Proliferator-Activated Receptors, Phase 3 trial, strategic, Tecentriq, United States Food and Drug Administration

Tempest Therapeutics , Amezalpat , Phase 3 Trial , Liver Cancer (HCC) , Strategic Partnerships , Biotech Funding , PPAR⍺ Antagonist , Clinical Oncology , FDA Clearance , Tecentriq and Avastin Combination Therapy

Alcon Secures Control of Aurion Biotech in Strategic Takeover

8 months ago talkbio0Tagged Alcon, AURN001, biotech, Bovichtus, Cell Therapy, CEO, corneal endothelial disease, IPO, stake, Surgical Replantation

Alcon, Aurion Biotech, majority stake, CEO replacement, cell therapy, corneal endothelial disease, AURN001, IPO dispute

Legal Battle Erupts as Deerfield Accuses Alcon of Obstructing Aurion Biotech’s IPO Plans

9 months ago talkbio0Tagged Alcon, biotech, biotech industry, Bovichtus, Chancery, Corporate, court, Deerfield Management, Delaware, governance, IPO, Legal, Public Offering, research, shareholder

Aurion Biotech, Alcon Research, Deerfield Management , Initial Public Offering (IPO), Legal dispute, Biotech industry, Corporate governance, Shareholder rights, Delaware Court of Chancery